Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCKDK | O14874 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 9/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31015945 | 0.90 | MCL1 (0.56) | BCKDKESR1KMOMCL1RAB9A | |
| SCHEMBL25237120 | 0.90 | MCL1 (0.56) | BCKDKESR1KMOMCL1RAB9A | |
| SCHEMBL25227374 | 0.85 | BCKDK (0.60) | BCKDKESR1MCL1RAB9ARXFP1 | |
| SCHEMBL25203086 | 0.82 | BCKDK (0.60) | BCKDKESR1MCL1RAB9ARXFP1 | |
| SCHEMBL25208186 | 0.82 | BCKDK (0.60) | BCKDKESR1MCL1RAB9ARXFP1 | |
| SCHEMBL25206581 | 0.81 | BCKDK (0.50) | BCKDKESR1RAB9ALMNA | |
| SCHEMBL25206962 | 0.81 | BCKDK (0.67) | BCKDKESR1MCL1RAB9ARXFP1 | |
| SCHEMBL25217782 | 0.81 | BCKDK (0.61) | BCKDKESR1MCL1RAB9ARXFP1 | |
| SCHEMBL25208237 | 0.81 | BCKDK (0.62) | BCKDKESR1MCL1RAB9ARXFP1 | |
| SCHEMBL25232009 | 0.81 | BCKDK (0.62) | BCKDKESR1MCL1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | BCKDK 1/4885ESR1 2725/4885KMO 82/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | BCKDK 1/4885ESR1 2725/4885KMO 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.